Vol.22 No.4

Case Report

Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies

Authors

Shinji Sato1 , Masataka Kuwana2 , Takashi Fujita3 , Yasuo Suzuki1

  • Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan
  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
  • Laboratory of Molecular Genetics, Institute for Virus Research, Kyoto University, 53 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
Received:

15 August 2011

Accepted:

1 November 2011

Published online:

29 November 2011

Full Text

PDF　(member's only)

Abstract

Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD). Here we report an amyopathic dermatomyositis (ADM) patient who developed RP-ILD characterized by elevated anti-CADM-140/MDA5 titer. Respiratory symptoms gradually improved, and anti-CADM-140/MDA5 titer decreased in parallel to below the cutoff level. It may be useful to quantify CADM-140-specific autoantibodies for monitoring disease activity in patients with ADM and RP-ILD.

Key words

Anti-CADM-140 autoantibodies - Anti-MDA5 autoantibodies - Clinically amyopathic dermatomyositis (CADM) - Dermatomyositis (DM) - Rapidly progressive interstitial lung disease (RP-ILD)